Investor Relations

Opportunity

Agile Life Sciences is an Enterprise Investment Scheme (EIS) qualifying Life Sciences company based in Flintshire, North Wales. 

We are grateful of the support received from the UK Research & Innovation (UKRI) including the following article: www.ukri.org/news/transforming-the-way-menopause-is-diagnosed-monitored-and-managed/

Why Invest?

Ground-breaking, patent protected science

Experienced and motivated team – each with equity (‘skin in the game’)

Large unmet market need for a menopause diagnostic

EIS qualifying (30% tax relief)

Previous Funding

Agile Life Sciences successfully closed a funding round of £200k in August 2022.  The funding round comprised “Angel” investors and was led by NorthInvest. This funding was matched by an Innovate UK grant for £200k under the Regional Accelerator Investment Award.

This combined funding of £400k facilitated critical laboratory capital equipment to be purchased and a comprehensive pilot study to be undertaken of 1,000 patients using our novel MenoGuide service, including a bespoke report for each patient.

Click to view the full Case study below in NorthInvest Annual Report.

 

 

 

Interested in Investing?

If you are interested in becoming an investor and benefiting from the 30% tax relief under the EIS scheme, then please fill out the following form and we will be in touch or email the Joint CEO peter.whitehurst@agilelifesciences.com

2 + 15 =

Location

Co-Workz, Flintshire

CH1 4QL 

Office Hours

Mon - Fri

8am-6pm

Accreditations

Agile Life Sciences has achieved certification to ISO13485 and operates an ISO15189-compliant laboratory quality management system.